Dr. Sudhakar Reddy P

Home  /  Dr. Sudhakar Reddy P

Dr. Sudhakar Reddy P

Dr. Sudhakar Reddy P

MBBS, MD, DM (Endocrinology)

Consultant Endocrinologist 

Qualification / Education:

  • MBBS: KMC Warangal 1993-99
  • MD: GMC Hyderabad 2001-2004
  • Registration No:43581
  • DM (Endocrinology): OMC  Hyderabad, 2004-07

Experience:

  • Worked as Consultant Endocrinologist at Yashoda hospital, Secunderabad from September 2007 to November 2016 (trained DNB students)
  • Currently working as a Chief Endocrinologist at Sunshine Hospital, Secunderabad since November 2016.

Expertise:

  • Diabetes
  • Thyroid
  • Bone disorders

Area of Interest:

  • Diabetes
  • Reproductive Endocrinology
  • Bone disorders
  • Lipid disorders
  • PG TEACHING

Publications:

  • Sudhakar R Pendyala, Role of Ultrasounds Thyroid Nodules, International Journal of scientific research, Volume-7, Issue-11, November 2018.
  • Baseline characteristics of patients on growth hormone therapy: Expérience of two centers from South India; Babulreddy Hanmayyagari, Mounika Guntaka1, Sunitha Chadalavada2, Voleti Sri Nagesh3, Sudhakar Reddy Pendyala4, Sridevi Patnala5 “Journal of Dr. NTR University of Health Sciences 2015;4(1) 17-20”
  • Premature Ovarian Failure in Autoimmune Polyglandular syndrome ” JBCRS_20_12
  • Newspaper article on Type-2 diabetics likely to suffer from memory loss, DECCAN CHRONICLE / INDULEKHA ARAKKAL, published: July 26, 2017.

Memberships:

  • Endocrine society of India (Membership No. LM 596)
  • Indian thyroid society
  • Telangana society of endocrinology
  • RSSDI
  • AACE

Awards and Honours:

  • Times health care achievers in Telugu states recognized as The Legend of the year 2018 in Endocrinology

Other:

  • Was a part of EDGE trial looking at effects of glucose reductions, CV safety with vildagliptin when added to the current regimen.
  • Was part of the DUALLTM VIII Trial, A 104-week study comparing long-term glycemic controls of insulin degludec/liraglutide (DegLira) versus insulin glargine therapy in subjects with type 2 diabetes mellitus. Trial ID: NN9068-4228
  • Was part of NN9536-4373/STEP-1 study where the effect and safety of albiglutide 2.4 mg once weekly in subjects with overweight or obesity was studied
  • DUAL VIII Trial: A 104-week study comparing long-term glycemic controls of insulin degludec/liraglutide (DegLira) versus insulin glargine therapy in subjects with type 2 diabetes mellitus. Trial ID: NN9068-4228
  • NN9536-4373: Effect and safety of semaglutide 2.4 mg once-weekly in subjects with overweight or obesity
  • Trail title: Semaglutide cardiovascular outcomes trial in patients with type 2 diabetes (SOUL)
  • Was part of IMPROVE control study
  • Was part of IDMPS wave 5 study

Hospital In Hyderabad